-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
China Medical City has formed key industrial clusters such as vaccines, antibody drugs, new chemical drug preparations, diagnostic reagents, high-end medical equipment, and special medical formula foods, with distinctive features and strong momentum
.
Since the beginning of this year, China Pharmaceutical City companies have been approved for 10 drug production licenses, and a total of 41 have been approved, and the pace of industrialization has been accelerating
.
The author has learned that recently, three more companies in China Medical City have successively obtained drug production licenses issued by the Jiangsu Provincial Drug Administration, and have officially entered the stage of industrialization
.
The three companies are An Ruowei he Taizhou Pharmaceutical Co.
, Ltd.
, Jiangsu Ren Honest Yi Pharmaceutical Co.
, Ltd.
Pharmaceutical Co.
, Ltd.
Jiangsu rule
.
The following author will take everyone into these three companies
.
Anrovita Pharmaceutical Taizhou Co.
, Ltd.
It is understood that on July 20, 2018, the project of Anrovita Pharmaceutical Taizhou Co.
, Ltd.
started in China Medical City
.
The project has a total investment of 100 million U.
S.
dollars, with an annual production of 3.
5 billion tablets and 500 million capsules.
The annual sales will reach 3 billion yuan after it is put into production
.
Anrovita Pharmaceutical Taizhou Co.
, Ltd.
is invested and constructed by Anrovita India headquarters
.
Anrovita India headquarters is a large multinational company, the second largest listed pharmaceutical company in India, with 25 factories or offices in China, the United States, Europe, South America, and South Africa
.
The company's products cover the fields of central nervous system, anti-HIV viral, cardiovascular, diabetes and gastrointestinal category, cephalosporins
.
Anrovita Pharmaceutical Taizhou Co.
, Ltd.
is mainly engaged in the R&D and industrialization of solid pharmaceutical preparations.
The company’s industrialization project covers an area of 97 acres and has a total construction area of 82,000 square meters.
Production and auxiliary facilities such as warehousing and logistics centers
.
Jiangsu Renhe Chengyi Pharmaceutical Co.
, Ltd.
Jiangsu Renhe Chengyi Pharmaceutical Co.
, Ltd.
settled in China Medical City in January 2019 with a registered capital of 100 million (yuan).
The business scope includes pharmaceutical production; reagents and pharmaceutical intermediates (excluding Hazardous chemicals) sales; medical technology research and development, technical consulting, technology transfer, technology promotion services
.
It is reported that the company's Jiangsu Renhechengyi Pharmaceutical Co.
, Ltd.
has two products, namely amlodipine besylate tablets and vildagliptin tablets, which will be launched soon
.
Among them, amlodipine besylate tablets are calcium channel blockers, suitable for the treatment of hypertension, and can be used alone or in combination with other antihypertensive drugs.
Technical review has been completed; vildagliptin tablets are for the digestive system And metabolic drugs, which are mainly used to treat type 2 diabetes, and the technical review is about to be completed
.
Jiangsu Zhongzhi Pharmaceutical Co.
, Ltd.
Jiangsu Zhongzhi Pharmaceutical Co.
, Ltd.
entered China Medical City in March 2019.
Its business scope includes the manufacturing of chemical raw materials and chemical preparations; the production of Chinese patent medicines and Chinese medicine extracts; and drug research and development
.
It is reported that Jiangsu Zhongzhi Pharmaceutical currently has two products, namely irbesartan hydrochlorothiazide tablets and calcitriol soft capsules, which are in the R&D and application stage
.
Among them, irbesartan hydrochlorothiazide tablets are used for the treatment of essential hypertension, and clinical studies have been completed and are in the reporting stage; calcitriol soft capsules are used for the treatment of postmenopausal osteoporosis, chronic failure, and postoperative parathyroidism Hypothyroidism, vitamin D-dependent rickets, etc.
, have completed pharmaceutical and pre-BE trials and are in the BE research stage
.
.
Since the beginning of this year, China Pharmaceutical City companies have been approved for 10 drug production licenses, and a total of 41 have been approved, and the pace of industrialization has been accelerating
.
The author has learned that recently, three more companies in China Medical City have successively obtained drug production licenses issued by the Jiangsu Provincial Drug Administration, and have officially entered the stage of industrialization
.
The three companies are An Ruowei he Taizhou Pharmaceutical Co.
, Ltd.
, Jiangsu Ren Honest Yi Pharmaceutical Co.
, Ltd.
Pharmaceutical Co.
, Ltd.
Jiangsu rule
.
The following author will take everyone into these three companies
.
Anrovita Pharmaceutical Taizhou Co.
, Ltd.
It is understood that on July 20, 2018, the project of Anrovita Pharmaceutical Taizhou Co.
, Ltd.
started in China Medical City
.
The project has a total investment of 100 million U.
S.
dollars, with an annual production of 3.
5 billion tablets and 500 million capsules.
The annual sales will reach 3 billion yuan after it is put into production
.
Anrovita Pharmaceutical Taizhou Co.
, Ltd.
is invested and constructed by Anrovita India headquarters
.
Anrovita India headquarters is a large multinational company, the second largest listed pharmaceutical company in India, with 25 factories or offices in China, the United States, Europe, South America, and South Africa
.
The company's products cover the fields of central nervous system, anti-HIV viral, cardiovascular, diabetes and gastrointestinal category, cephalosporins
.
Anrovita Pharmaceutical Taizhou Co.
, Ltd.
is mainly engaged in the R&D and industrialization of solid pharmaceutical preparations.
The company’s industrialization project covers an area of 97 acres and has a total construction area of 82,000 square meters.
Production and auxiliary facilities such as warehousing and logistics centers
.
Jiangsu Renhe Chengyi Pharmaceutical Co.
, Ltd.
Jiangsu Renhe Chengyi Pharmaceutical Co.
, Ltd.
settled in China Medical City in January 2019 with a registered capital of 100 million (yuan).
The business scope includes pharmaceutical production; reagents and pharmaceutical intermediates (excluding Hazardous chemicals) sales; medical technology research and development, technical consulting, technology transfer, technology promotion services
.
It is reported that the company's Jiangsu Renhechengyi Pharmaceutical Co.
, Ltd.
has two products, namely amlodipine besylate tablets and vildagliptin tablets, which will be launched soon
.
Among them, amlodipine besylate tablets are calcium channel blockers, suitable for the treatment of hypertension, and can be used alone or in combination with other antihypertensive drugs.
Technical review has been completed; vildagliptin tablets are for the digestive system And metabolic drugs, which are mainly used to treat type 2 diabetes, and the technical review is about to be completed
.
Jiangsu Zhongzhi Pharmaceutical Co.
, Ltd.
Jiangsu Zhongzhi Pharmaceutical Co.
, Ltd.
entered China Medical City in March 2019.
Its business scope includes the manufacturing of chemical raw materials and chemical preparations; the production of Chinese patent medicines and Chinese medicine extracts; and drug research and development
.
It is reported that Jiangsu Zhongzhi Pharmaceutical currently has two products, namely irbesartan hydrochlorothiazide tablets and calcitriol soft capsules, which are in the R&D and application stage
.
Among them, irbesartan hydrochlorothiazide tablets are used for the treatment of essential hypertension, and clinical studies have been completed and are in the reporting stage; calcitriol soft capsules are used for the treatment of postmenopausal osteoporosis, chronic failure, and postoperative parathyroidism Hypothyroidism, vitamin D-dependent rickets, etc.
, have completed pharmaceutical and pre-BE trials and are in the BE research stage
.
